2024
The amalgam of naive CD4+ T cell transcriptional states is reconfigured by helminth infection to dampen the amplitude of the immune response
Even Z, Meli A, Tyagi A, Vidyarthi A, Briggs N, de Kouchkovsky D, Kong Y, Wang Y, Waizman D, Rice T, De Kumar B, Wang X, Palm N, Craft J, Basu M, Ghosh S, Rothlin C. The amalgam of naive CD4+ T cell transcriptional states is reconfigured by helminth infection to dampen the amplitude of the immune response. Immunity 2024, 57: 1893-1907.e6. PMID: 39096910, PMCID: PMC11421571, DOI: 10.1016/j.immuni.2024.07.006.Peer-Reviewed Original ResearchT cell receptorImmune responseNaive CD4<sup>+</sup> T cellsCD4<sup>+</sup> T cellsIFN-IHelminth infectionsNippostrongylus brasiliensis infectionDecreased immune responseType I interferonNaive TT cellsMemory-likeUnrelated antigensTranscriptional changesExtracellular matrixSPF miceCell receptorsI interferonGerm-freeResponse to certain environmental cuesInfectionMiceFunctional changesCell transcriptional statesTranscriptional heterogeneity
2023
Response to comment on “Dosing implications for liposomal amphotericin B in pregnancy”
O'Grady N, Davis M, McManus D, Topal J, Azar M, Briggs N. Response to comment on “Dosing implications for liposomal amphotericin B in pregnancy”. Pharmacotherapy The Journal Of Human Pharmacology And Drug Therapy 2023, 43: 992-992. PMID: 37701938, DOI: 10.1002/phar.2864.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDosing implications for liposomal amphotericin B in pregnancy
O'Grady N, McManus D, Briggs N, Azar M, Topal J, Davis M. Dosing implications for liposomal amphotericin B in pregnancy. Pharmacotherapy The Journal Of Human Pharmacology And Drug Therapy 2023, 43: 452-462. PMID: 36862037, DOI: 10.1002/phar.2784.Peer-Reviewed Original ResearchConceptsIdeal body weightLiposomal amphotericin BMucocutaneous leishmaniasisBody weightAmphotericin BInfectious Diseases SocietyTotal body weightPregnant patientsDiseases SocietyAmerica guidelinesPreferred agentPregnancyParasitic infectionsOpportunistic fungalAdverse effectsPatientsTreatmentLeishmaniasisLambsDaysUse of lambsGuidelinesRegimensWeightFetuses
2022
Mucocutaneous Leishmaniasis in a Pregnant Immigrant
Briggs N, Wei BM, Ahuja C, Baker C, Palacios C, Lee E, O’Grady N, Singanamala S, Singh K, Bandaranayake TD, Cohen JM, Damsky W, Davis MW, Mejia R, Nelson CA, Topal JE, Azar MM. Mucocutaneous Leishmaniasis in a Pregnant Immigrant. Open Forum Infectious Diseases 2022, 9: ofac360. PMID: 35928503, PMCID: PMC9345408, DOI: 10.1093/ofid/ofac360.Peer-Reviewed Original ResearchEfficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.Peer-Reviewed Original ResearchConceptsCCP recipientsPlacebo recipientsSecondary outcomesSymptom durationHospitalized patientsPrimary outcomeDay 28COVID-19SARS-CoV-2 serostatusSARS-CoV-2 titersWorld Health Organization (WHO) ordinal scaleCOVID-19 convalescent plasmaConvalescent plasma usePlacebo-controlled trialLess daysExploratory subgroup analysisNon-Hispanic blacksSARS-CoV-2CCP efficacyConcomitant medicationsAdverse eventsClinical improvementSymptom onsetConvalescent plasmaMedian age
2021
Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere disease
2020
Advances in rapid diagnostics for bloodstream infections
Briggs N, Campbell S, Gupta S. Advances in rapid diagnostics for bloodstream infections. Diagnostic Microbiology And Infectious Disease 2020, 99: 115219. PMID: 33059201, DOI: 10.1016/j.diagmicrobio.2020.115219.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2018
Trichuris muris whey acidic protein induces type 2 protective immunity against whipworm
Briggs N, Wei J, Versteeg L, Zhan B, Keegan B, Damania A, Pollet J, Hayes KS, Beaumier C, Seid CA, Leong J, Grencis RK, Bottazzi ME, Sastry KJ, Hotez PJ. Trichuris muris whey acidic protein induces type 2 protective immunity against whipworm. PLOS Pathogens 2018, 14: e1007273. PMID: 30153307, PMCID: PMC6130879, DOI: 10.1371/journal.ppat.1007273.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseImmune correlatesLymph nodesProtective immunityT helper type 2 immune responseT. murisType 2 immune responsesIgE-mediated allergic responsesTh2 cytokines IL-4Adult T. murisAntigen-specific productionCellular immune correlatesHumoral immune correlatesMesenteric lymph nodesInguinal lymph nodesMontanide ISA 720Cytokines IL-4Control of infectionLow drug efficacySubcutaneous vaccineBowel diseaseInfectious causesOral challengeISA 720Protective efficacy
2017
Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response
Wei J, Versteeg L, Liu Z, Keegan B, Gazzinelli-Guimarães AC, Fujiwara RT, Briggs N, Jones KM, Strych U, Beaumier CM, Bottazzi ME, Hotez PJ, Zhan B. Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response. PLOS Neglected Tropical Diseases 2017, 11: e0005769. PMID: 28708895, PMCID: PMC5529013, DOI: 10.1371/journal.pntd.0005769.Peer-Reviewed Original ResearchConceptsTh2-skewed immune responseTh2-type responseCholera toxin B subunitImmune responseEgg challengeProtective immunitySignificant protectionPredominant Th2-type responseTh2-type immune responseFeasible vaccine candidateTh1-type responseCommon helminth infectionA. suum infectionAscaris suum infectionExact protective mechanismHost immune systemToxin B subunitA. suumRestimulated splenocytesA. suum eggsChallenge infectionIL-4IL-5Trichuris infectionHelminth infections
2016
The Hygiene Hypothesis and Its Inconvenient Truths about Helminth Infections
Briggs N, Weatherhead J, Sastry KJ, Hotez PJ. The Hygiene Hypothesis and Its Inconvenient Truths about Helminth Infections. PLOS Neglected Tropical Diseases 2016, 10: e0004944. PMID: 27632204, PMCID: PMC5025185, DOI: 10.1371/journal.pntd.0004944.Peer-Reviewed Original Research
2014
Universal Artificial Antigen Presenting Cells to Selectively Propagate T Cells Expressing Chimeric Antigen Receptor Independent of Specificity
Rushworth D, Jena B, Olivares S, Maiti S, Briggs N, Somanchi S, Dai J, Lee D, Cooper LJ. Universal Artificial Antigen Presenting Cells to Selectively Propagate T Cells Expressing Chimeric Antigen Receptor Independent of Specificity. Journal Of Immunotherapy 2014, 37: 204-213. PMID: 24714354, PMCID: PMC4139067, DOI: 10.1097/cji.0000000000000032.Peer-Reviewed Original ResearchAdvancing a multivalent ‘Pan-anthelmintic’ vaccine against soil-transmitted nematode infections
Zhan B, Beaumier CM, Briggs N, Jones KM, Keegan BP, Bottazzi ME, Hotez PJ. Advancing a multivalent ‘Pan-anthelmintic’ vaccine against soil-transmitted nematode infections. Expert Review Of Vaccines 2014, 13: 321-331. PMID: 24392641, PMCID: PMC3934375, DOI: 10.1586/14760584.2014.872035.Peer-Reviewed Original ResearchConceptsSoil-transmitted nematode infectionsPhase 1 clinical testingAntigen selectionHelminth-endemic regionsSabin Vaccine Institute Product Development PartnershipAntigen-specific IgEHuman hookworm vaccineProtective immunityHookworm infectionHookworm vaccinePreclinical evaluationClinical developmentClinical testingAntigen discoveryNematode infectionVaccineInfectionAntigenProduct development partnershipsAscaris eggsIgEAscariasisTrichuriasisAscarisImmunity
2013
Stacking nonenzymatic circuits for high signal gain
Chen X, Briggs N, McLain JR, Ellington AD. Stacking nonenzymatic circuits for high signal gain. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 5386-5391. PMID: 23509255, PMCID: PMC3619317, DOI: 10.1073/pnas.1222807110.Peer-Reviewed Original ResearchConceptsSignal amplificationCare molecular diagnosticsSignal amplification schemeMolecular diagnosticsHigh signal gainDynamic DNA hybridizationCircuit leakageDNA circuitsAmplification cascadeDNA hybridizationExponential amplificationProgrammable formAmplification schemeTwo-layer cascadeGreat potentialSignal gainStrand displacementUnique methodProtein enzymes